Suchergebnisse - "Brufsky, Adam"

PubPharm (37)

1

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802) : a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial

enthalten in: The Lancet. Oncology | 2024

von Palmieri, C. | Linden, H. | Birrell, S. | +12

ErratumIn: Lancet Oncol. 2024 Apr;25(4):e137. - PMID 38547897

2

A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression

enthalten in: JCO precision oncology | 2023

von Brett, J. | Dubash, T. | Johnson, G. | +29

3

MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice

enthalten in: JNCI cancer spectrum | 2021

von Paterson, A. | Lucas, P. | Anderson, S. | +14

4

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2021

von Bardia, A. | Hurvitz, S. | Tolaney, S. | +117

CommentIn: Nat Rev Clin Oncol. 2021 Jun;18(6):322. - PMID 33931767

5

TBCRC 048 : Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Tung, N. | Robson, M. | Ventz, S. | +22

6

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens : Phase III NALA Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Saura, C. | Oliveira, M. | Feng, Y. | +33

CommentIn: J Clin Oncol. 2021 Jan 20;39(3):251-252. - PMID 33332187

7

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA) : end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2020

von Swain, S. | Miles, D. | Kim, S. | +113

CommentIn: Lancet Oncol. 2020 Apr;21(4):471-472. - PMID 32171427

8

Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Cobleigh, M. | Yardley, D. | Brufsky, A. | +11

9

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

enthalten in: The New England journal of medicine | 2020

von Modi, S. | Saura, C. | Yamashita, T. | +99

CommentIn: Cancer Discov. 2020 Feb;10(2):167. - PMID 31843763

10

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

enthalten in: The New England journal of medicine | 2019

von Sparano, J. | Gray, R. | Ravdin, P. | +27

CommentIn: N Engl J Med. 2019 Sep 26;381(13):1289-1291. - PMID 31553844